Identifying genetic markers to distinguish between benign and malignant myeloma precursor conditions
Myeloma Defining Genomic Events to Differentiate Benign and Malignant Myeloma Precursor Conditions
This study is looking at the genetic changes that can help tell if someone with a benign condition related to multiple myeloma might develop the disease, so we can find out who is at higher risk and help them sooner.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project ID | NIH-11050304 on NIH RePORTER |
What this research studies
This research investigates the genetic events that differentiate benign conditions from malignant multiple myeloma precursor stages. By utilizing advanced whole genome sequencing, the study aims to identify critical genomic markers that indicate whether a patient’s condition is stable or likely to progress to multiple myeloma. The goal is to enable early identification of high-risk patients, allowing for timely intervention and prevention strategies. This approach could significantly improve patient outcomes by addressing a major unmet clinical need in the management of myeloma precursor conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults diagnosed with benign monoclonal gammopathy or smoldering myeloma who are at risk of progression to multiple myeloma.
Not a fit: Patients who have already been diagnosed with symptomatic multiple myeloma or those without any precursor conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and prevention strategies for patients at risk of developing multiple myeloma.
How similar studies have performed: Previous research has shown success in using whole genome sequencing to identify genomic events in various cancers, suggesting that this approach may be effective in the context of myeloma precursor conditions as well.
Where this research is happening
Coral Gables, United States
- University of Miami School of Medicine — Coral Gables, United States (Active)
Researchers
- Principal investigator: Maura, Francesco — University of Miami School of Medicine
- Study coordinator: Maura, Francesco
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.